DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB:NEOP) today announced financial results for the fourth quarter of 2006 and for the full year that ended December 31, 2006. Results for the fourth quarter and for the full year of 2006 include the consolidated operations of Neoprobe Corporation and its subsidiaries, Cardiosonix Ltd. and Cira Biosciences, Inc. For the fourth quarter of 2006, Neoprobe had a net loss of $1.3 million (including total non-cash expenses of $398,000) or $0.02 per share compared to loss of $1.3 million (including total non-cash expenses of $326,000) or $0.02 per share for the fourth quarter of 2005. For fiscal year 2006, Neoprobe incurred a net loss of $4.7 million (including total non-cash expenses of $1.5 million) or $0.08 per share compared to a net loss of $4.9 million (including total non-cash expenses of $1.4 million) or $0.08 per share for fiscal 2005.
